Silent struggle, unseen impact: Endometriosis demands equality in research and awareness

Did you know that endometriosis affects roughly as many women as diabetes or asthma? This invisible disease silently inflicts decades of chronic and acute pain on millions of individuals. Despite its prevalence, endometriosis receives significantly less attention and research funding compared to other common diseases.

Let's raise awareness to drive change! Together, we can work towards better treatments, early detection, and accurate diagnosis for all women affected by this debilitating condition.

March is Endometriosis Awareness Month. Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients.

Learn more about endometriosis:

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.